Clinical Trials on PD-1 Refractory Advanced Melanoma
Total 677 results
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Diwakar DavarMerck Sharp & Dohme LLC; Gateway for Cancer ResearchNot yet recruitingPD-1 Refractory Advanced MelanomaUnited States
-
Fudan UniversityNot yet recruitingthe Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced MelanomaChina
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
University Hospital HeidelbergDepartment of Dermatology, Heidelberg University HospitalCompletedMelanoma | Exercise | PD-1 AntibodiesGermany
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)RecruitingRefractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H TumorsUnited States
-
Xijing HospitalRecruitingPD-1 | Locally Advanced Gastric AdenocarcinomaChina
-
Gregory DanielsImmunotherapy FoundationRecruitingMetastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck CancerUnited States
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Peking UniversityNot yet recruitingGastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
-
AstraZenecaCompletedRefractory MelanomaUnited States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMetastatic Melanoma | Advanced MelanomaChina
-
Azienda Ospedaliera di PerugiaNot yet recruitingAdvanced Melanoma | Early MelanomaItaly, Sweden, France, Germany, Netherlands, Poland, Spain
-
Cancer Trials IrelandCompletedMetastatic Melanoma | Advanced MelanomaIreland
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Krankenhaus NordwestTerminatedChemo-refractory MelanomaGermany
-
Fachklinik Hornheide an der Universität MünsterUnknownAdvanced Metastastic Malignant Melanoma | Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue MetastasesGermany
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Metastatic Melanoma | Advanced Non-hematologic MalignanciesUnited States
-
Institute of Oncology LjubljanaUniversity of Ljubljana; Military Medical Academy, Belgrade, SerbiaRecruitingMetastatic Melanoma | Immune Checkpoints Inhibitors | Gastrointestinal Microbiome (Bacterial and Viral) | Exosomal mRNA Expression of PD-L1 and IFNγSlovenia
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Acral Malignant MelanomaChina
-
Elizabeth DavisBristol-Myers SquibbTerminatedMetastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II ExpressionUnited States
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | G-CSFChina
-
Beijing Friendship HospitalNot yet recruiting
-
Replimune Inc.Not yet recruiting
-
University Hospital, Basel, SwitzerlandAnaveon AGRecruiting
-
Henan Cancer HospitalRecruitingAdvanced MelanomaChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Agenus Inc.SuspendedAdvanced MelanomaUnited States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
-
RAPT Therapeutics, Inc.Terminated
-
Lytix Biopharma ASLaboratory Corporation of America; OWLActive, not recruitingAdvanced MelanomaUnited States, Spain, France, Norway
-
Peking University Cancer Hospital & InstituteUnknown
-
Bristol-Myers SquibbCompletedAdvanced MelanomaUnited States, United Kingdom
-
University of RegensburgClinAssess GmbHUnknown
-
Genta IncorporatedCompleted
-
Herlev HospitalCompleted
-
Mannkind CorporationCompletedAdvanced Melanoma | Stage III and IV MelanomaUnited States
-
BiocadRecruitingAdvanced MelanomaRussian Federation, Belarus
-
University of California, San FranciscoMerck Sharp & Dohme LLCRecruitingMelanoma | Advanced MelanomaUnited States